abstract |
The present invention generally relates to the lanostast, a family of tetracyclic terpenols, as anti-inflammatory, anti-carcinogenic and analgesic agents by inhibiting the perturbed activation of serine-threonine protein kinases, specifically PKC. It relates to the pharmaceutical use of -8,24-dien-3-ol. [Selection] Figure 1 |